TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21836549

Group type: EXPERIMENTAL
Intervention: Intervention group with enhanced support for maternal-infant bonding, including information about newborn behaviors and encouragement for skin-to-skin contact.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving weekly encouragement to remain smoke free and routine breastfeeding support.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention group with enhanced support for maternal-infant bonding.
Number of subjects: 0
Study: 21162922

Group type: EXPERIMENTAL
Intervention: Periarticular injection of ropivacaine, morphine and epinephrine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Patient‐controlled epidural analgesia (PCEA)
Number of subjects: 36
Study: 17923867

Group type: EXPERIMENTAL
Intervention: Intensive CEP (C 1800 mg m(‐2), E 50 mg m(‐2), P 75 mg m(‐2) with filgrastim 5 mug kg(‐1) per day x 10 days)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Standard CEP (C 500 mg m(‐2), E 50 mg m(‐2), P 75 mg m(‐2))
Number of subjects: 164
Study: 15716329

Group type: EXPERIMENTAL
Intervention: Olmesartan (40 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 12496748

Group type: EXPERIMENTAL
Intervention: Propofol 6%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propofol 1%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol 6% and 1%
Number of subjects: 20
Study: 9818309

Group type: EXPERIMENTAL
Intervention: Cambridge Contextual Reading Test (CCRT)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: National Adult Reading Test (NART)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Spot‐the‐Word Test (STW)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 21
Study: 7516001

Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2913893

Group type: EXPERIMENTAL
Intervention: Standard 6-min treadmill run (S1A)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Standard 6-min treadmill run (S2A)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 30-min treadmill run at a lower gradient (W1B)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Standard 6-min treadmill run (S2B)
Number of subjects: 7
Study: 29706210

Group type: EXPERIMENTAL
Intervention: Amoxicillin (antibiotic prophylaxis)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Glucose (placebo control)
Number of subjects: 38
Study: 27472560

Group type: EXPERIMENTAL
Intervention: LEAP (web-based intervention promoting healthy eating, physical activity, and social connections)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: LEAP (web-based intervention)
Number of subjects: 75
Study: 24666802

Group type: EXPERIMENTAL
Intervention: Website
Number of subjects: 40

Group type: COMPARATOR
Intervention: Printed leaflet
Number of subjects: 40
Study: 22898578

Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit™ training
Number of subjects: 27
Study: 20177681

Group type: EXPERIMENTAL
Intervention: 4,000 IU/day low molecular weight heparin (LMWH) prophylaxis
Number of subjects: 60
Study: 18267051

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 80/4.5 microg (160/9 microg)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Formoterol DPI 4.5 microg (9 microg)
Number of subjects: 480
Study: 16970101

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA), n = 23
Number of subjects: 46

Group type: COMPARATOR
Intervention: Nimotop, n = 23
Number of subjects: 46
Study: 12935823

Group type: EXPERIMENTAL
Intervention: Troponin T levels >0.1 microg/L
Number of subjects: 7115

Group type: COMPARATOR
Intervention: Troponin T levels <=0.1 microg/L
Number of subjects: 7115

Group type: EXPERIMENTAL
Intervention: Troponin T cutoff value 0.03 microg/L
Number of subjects: 7115

Group type: EXPERIMENTAL
Intervention: Troponin T cutoff value 0.01 microg/L
Number of subjects: 7115

Group type: EXPERIMENTAL
Intervention: Troponin T cutoff value <=0.01 microg/L
Number of subjects: 7115
Study: 10673519

Group type: EXPERIMENTAL
Intervention: G-CSF (filgrastim) administered at a daily dose of 5 microg/kg after two courses of intensive consolidation chemotherapy (ICC)
Number of subjects: 194
Study: 8790153

Group type: COMPARATOR
Intervention: Heparin-coated circuits (Duraflo II) and reduced systemic heparinization (ACT > 250s)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Non-coated circuits and standard heparin administration (ACT > 480s)
Number of subjects: 22
Study: 7969680

Group type: EXPERIMENTAL
Intervention: Diuretic treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 3H‐ANG(1‐8) infusion (0.5, 2.0, and 2.5 ng/kg/min)
Number of subjects: 28
Study: 3593628

Group type: EXPERIMENTAL
Intervention: Ibopamine administered immediately after a meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ibopamine administered 2 hours after a meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ibopamine administered 0.5 hours before a meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ibopamine administered 3 hours after a meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ibopamine administered in fasting state
Number of subjects: 12
Study: 29768633

Group type: EXPERIMENTAL
Intervention: Speech Recognition (SR)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Keyboard and Mouse (KBM)
Number of subjects: 35
Study: 28131081

Group type: EXPERIMENTAL
Intervention: 2g γ‐glutamylcysteine (γ‐GC)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 4g γ‐glutamylcysteine (γ‐GC)
Number of subjects: 14
Study: 26775547

Group type: EXPERIMENTAL
Intervention: CABG and PVI using intraoperative irrigated radiofrequency ablation (CABG+PVI)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: CABG and MM procedure using intraoperative irrigated radiofrequency ablation (CABG+MM)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Isolated CABG (CABG alone)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: CABG+PVI and CABG+MM
Number of subjects: 95
Study: 23432964

Group type: EXPERIMENTAL
Intervention: BMI <25 kg/m2 (normal weight)
Number of subjects: 5495

Group type: COMPARATOR
Intervention: BMI >25 kg/m2 (overweight and obese)
Number of subjects: 5495
Study: 21957976

Group type: EXPERIMENTAL
Intervention: Telmisartan-based plus simvastatin therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Telmisartan-based monotherapy
Number of subjects: 41
Study: 18781668

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT-MOMS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nondepressed mothers of healthy children
Number of subjects: 22
Study: 16680067

Group type: EXPERIMENTAL
Intervention: CEE/MPA (conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 5 mg)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: E2/NETA (17beta‐estradiol 2 mg plus norethisterone acetate 1 mg)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Low E2/NETA (17beta‐estradiol 1 mg plus norethisterone acetate 0.5 mg)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg)
Number of subjects: 519
Study: 15238182

Group type: EXPERIMENTAL
Intervention: Proportional adjustment group
Number of subjects: 75

Group type: COMPARATOR
Intervention: Target adjustment group
Number of subjects: 75
Study: 11742965

Group type: EXPERIMENTAL
Intervention: Protocols for liberating patients from MV driven by nonphysician HCPs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spontaneous breathing trial (SBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ventilator management strategies for patients failing SBT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pressure support ventilation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeating a trial of spontaneous breathing
Number of subjects: 0
Study: 8764716

Group type: EXPERIMENTAL
Intervention: Banked cultured human epidermal allografts
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 20
Study: 1799474

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b 5 million units subcutaneously three times weekly until progression or relapse
Number of subjects: 19

Group type: COMPARATOR
Intervention: Prednimustine and mitoxantrone (PmM) regimen
Number of subjects: 19

Group type: COMPARATOR
Intervention: Historical comparison to unmaintained first remission
Number of subjects: 19
Study: 6656960

Group type: COMPARATOR
Intervention: Radiotherapy (60 Gy)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Combined treatment (radiotherapy with chemotherapy: methotrexate and 5-fluorouracil)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Combined treatment (radiotherapy with chemotherapy)
Number of subjects: 174
Study: 31092823

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccine
Number of subjects: 1028

Group type: COMPARATOR
Intervention: Baseline CSP IgG levels
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: IgG magnitude to NANP post-vaccination
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: IgG avidity to C-terminus post-vaccination
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: IgG avidity to C-terminus
Number of subjects: 1028
Study: 28648704

Group type: EXPERIMENTAL
Intervention: Bicruciate-stabilized implant
Number of subjects: 228

Group type: COMPARATOR
Intervention: Posterior-stabilized implant
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Both groups (AEs)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Both groups (revisions)
Number of subjects: 228
Study: 25889509

Group type: EXPERIMENTAL
Intervention: Selenium (200 μg/d L-selenomethionine)
Number of subjects: 1641

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU/day all rac-α-tocopheryl acetate)
Number of subjects: 1641

Group type: EXPERIMENTAL
Intervention: Selenium combined with Vitamin E
Number of subjects: 1641

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1641
Study: 24094658

Group type: EXPERIMENTAL
Intervention: 3D laparoscopy
Number of subjects: 33

Group type: COMPARATOR
Intervention: 2D laparoscopy
Number of subjects: 33
Study: 21292922

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 174

Group type: COMPARATOR
Intervention: Haloperidol, Risperidone, Olanzapine
Number of subjects: 174
Study: 19303575

Group type: EXPERIMENTAL
Intervention: Perindopril 8mg/day
Number of subjects: 10962

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10962
Study: 17726586

Group type: EXPERIMENTAL
Intervention: Intra-articular ketamine (0.25 mg S-(+)-ketamine/kg body weight in 10 ml 0.9% NaCl)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.25 mg S-(+)-ketamine/kg body weight)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intra-articular bupivacaine (10 ml 0.25% bupivacaine)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (10 ml 0.9% NaCl)
Number of subjects: 68
Study: 15481068

Group type: EXPERIMENTAL
Intervention: Snoezelen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reminiscence therapy
Number of subjects: 20
Study: 11578884

Group type: EXPERIMENTAL
Intervention: PGE(1) 25 ng/kg/min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PGE(1) 50 ng/kg/min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (saline infusion)
Number of subjects: 40
Study: 9562230

Group type: EXPERIMENTAL
Intervention: Sertindole 20 mg daily
Number of subjects: 13

Group type: COMPARATOR
Intervention: Terfenadine alone
Number of subjects: 13
Study: 7651057

Group type: EXPERIMENTAL
Intervention: N-acetylcysteïne (NAC) 3 x 600 mg per day for 5 days, starting 5 or 10 days after Photofrin
Number of subjects: 27

Group type: COMPARATOR
Intervention: N-acetylcysteïne (NAC)
Number of subjects: 27
Study: 2689182

Group type: EXPERIMENTAL
Intervention: Diltiazem (360 mg per day orally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate (4 g.m-2 body surface area)
Number of subjects: 0
Study: 766724

Group type: EXPERIMENTAL
Intervention: Laxogas gas producing suppositories
Number of subjects: 0
Study: 30952672

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg IV every 3 weeks for up to 8 cycles, starting within 21 days of post-ASCT discharge)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 30
Study: 29949271

Group type: EXPERIMENTAL
Intervention: Two-step method for shoulder delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: One-step method for shoulder delivery
Number of subjects: 0
Study: 24699943

Group type: EXPERIMENTAL
Intervention: Integrated and culturally attuned CBT group treatment (n = 18)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Individual counseling services (Control group, n = 20)
Number of subjects: 38
Study: 23429358

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: CYP2C19 loss-of-function allele carriers (*1/*2 or *3, *2/*2 or *3)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Recurrent CV events
Number of subjects: 109
Study: 21148683

Group type: EXPERIMENTAL
Intervention: Xevonta Hi 23 (Amembris(®))
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: FX dialysers
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Xenium 210 (Purema(®))
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: SDS‐PAGE scanning
Number of subjects: 18
Study: 19735532

Group type: COMPARATOR
Intervention: Interictal SAT in migraineurs (mean SAT averaged for 1000, 4000, and 8000 Hz)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Ictal SAT in migraineurs (mean SAT averaged for 1000, 4000, and 8000 Hz)
Number of subjects: 112
Study: 16548081

Group type: EXPERIMENTAL
Intervention: Acupuncture including electroacupuncture
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sensory stimulation with high‐intensity, low‐frequency transcutaneous electrical nerve stimulation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Low‐intensity (subliminal) high‐frequency transcutaneous electrical nerve stimulation
Number of subjects: 54
Study: 15473337

Group type: EXPERIMENTAL
Intervention: Punctures performed at an insertion angle of 50‐60 degrees
Number of subjects: 100

Group type: COMPARATOR
Intervention: Punctures performed at an insertion angle of 90 degrees
Number of subjects: 100
Study: 10969346

Group type: EXPERIMENTAL
Intervention: Genotypic guided treatment
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 107
Study: 9428983

Group type: EXPERIMENTAL
Intervention: Biapenem 500 mg administered intravenously over 30 min
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Biapenem administered after haemodialysis or in double the dose on haemodialysis days
Number of subjects: 38
Study: 7679869

Group type: EXPERIMENTAL
Intervention: Benazepril (20 mg) and Hydrochlorothiazide (50 mg) for 3 months
Number of subjects: 14

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg) for 3 months
Number of subjects: 14
Study: 3704892

Group type: EXPERIMENTAL
Intervention: Tetracycline sclerotherapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (drains left in place)
Number of subjects: 14
Study: 31848562

Group type: EXPERIMENTAL
Intervention: Microbead enrichment technique using an optoelectrokinetic platform with dual biomarkers (lipocalin 1 and vascular endothelial growth factor) for screening DR
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Concentration thresholds of LCN1 and VEGF for indicating proliferative DR
Number of subjects: 24
Study: 29194772

Group type: EXPERIMENTAL
Intervention: Aspirin 1 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Clopidogrel 2 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combination therapy (Aspirin + Clopidogrel)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 6
Study: 27473139

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) 20 mg daily
Number of subjects: 43

Group type: COMPARATOR
Intervention: Interferon β-1b (IFN‐β‐1b) 250 μg subcutaneous every other day
Number of subjects: 43
Study: 24093828

Group type: EXPERIMENTAL
Intervention: CyberSenga Internet-based program (five lessons + booster)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Treatment-as-usual control
Number of subjects: 366
Study: 21890236

Group type: EXPERIMENTAL
Intervention: Online care
Number of subjects: 64

Group type: COMPARATOR
Intervention: In-office care
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study: 19815651

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (70 mg/m² on days 1, 8, and 15) combined with carboplatin (AUC = 6 on day 1)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard paclitaxel (200 mg/m² on day 1) combined with carboplatin (AUC = 6 on day 1)
Number of subjects: 82
Study: 19101902

Group type: EXPERIMENTAL
Intervention: Triamcinolone 1% ointment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Water-based gel (control)
Number of subjects: 70
Study: 15687421

Group type: EXPERIMENTAL
Intervention: Intervention group (individual, routine, preventive, outpatient visit with trained primary care physicians)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (usual verbal encouragement and routine visits)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 226
Study: 11837952

Group type: EXPERIMENTAL
Intervention: Bright white light (2,700 lux)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Dim red light placebo (0.1 lux)
Number of subjects: 54
Study: 10084064

Group type: EXPERIMENTAL
Intervention: Very low molecular weight heparin (OP 2000)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 120
Study: 7486089

Group type: EXPERIMENTAL
Intervention: Epinephrine 7.5 group (3 mL 1.5% lidocaine containing 7.5 micrograms epinephrine)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epinephrine 15 group (3 mL 1.5% lidocaine containing 15 micrograms epinephrine)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epinephrine 22.5 group (3 mL 1.5% lidocaine containing 22.5 micrograms epinephrine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline group (3 mL normal saline)
Number of subjects: 80
Study: 2256443

Group type: EXPERIMENTAL
Intervention: Tegretol Retard
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trimonil Retard
Number of subjects: 0
Study: 399436

Group type: EXPERIMENTAL
Intervention: Coccinia indica preparation (experimental group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Dummy group (control group)
Number of subjects: 32
Study: 31567576

Group type: EXPERIMENTAL
Intervention: Self-warming blanket
Number of subjects: 112

Group type: COMPARATOR
Intervention: Forced-air-warming blanket
Number of subjects: 112
Study: 27327849

Group type: EXPERIMENTAL
Intervention: Gum chewing (sugar-free gum every 2 hours for 20 minutes from the end of drinking 2 L of PEG to the beginning of colonoscopy)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (2 L of PEG before colonoscopy)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Gum chewing
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control
Number of subjects: 300
Study: 25886781

Group type: EXPERIMENTAL
Intervention: ALS-MITOS system
Number of subjects: 200
Study: 23677743

Group type: EXPERIMENTAL
Intervention: Finely crushed ORF tablets
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Coarsely crushed ORF tablets
Number of subjects: 30

Group type: COMPARATOR
Intervention: Finely crushed OC tablets
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nasal tolerability (ORF vs OC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall safety profile
Number of subjects: 30
Study: 21437161

Group type: EXPERIMENTAL
Intervention: Carvedilol-loaded stents
Number of subjects: 41

Group type: COMPARATOR
Intervention: Bare-metal stents (Control)
Number of subjects: 41
Study: 20137493

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic therapy without antibiotic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CWDB and wide-type bacteria stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (chronic tonsillitis patients)
Number of subjects: 0
Study: 17298307

Group type: EXPERIMENTAL
Intervention: Suction drainage (Group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No suction drainage (Group A)
Number of subjects: 100
Study: 15210458

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall costs comparison
Number of subjects: 0
Study: 11426771

Group type: EXPERIMENTAL
Intervention: Colforsin treatment (0.5 microg.kg(‐1).min(‐1) for 6 hours)
Number of subjects: 29

Group type: COMPARATOR
Intervention: No colforsin treatment (control)
Number of subjects: 29
Study: 9714133

Group type: EXPERIMENTAL
Intervention: APOA4-2 allele carriers
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: NCEP-I diet
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: A/A individuals after dietary intervention
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: APOA4-360-2 allele
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: APOA4-347-T allele
Number of subjects: 67
Study: 8283157

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 2002

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2002
Study: 2597599

Group type: EXPERIMENTAL
Intervention: Benfluorex (three tablets/day) for six months (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dietary measures only (Group B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Benfluorex in NIDDM patients (Group A)
Number of subjects: 50
Study: 5570647

Group type: EXPERIMENTAL
Intervention: Phenobarbitone administration alongside methyldopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methyldopa alone
Number of subjects: 0
Study: 30784008

Group type: EXPERIMENTAL
Intervention: Visible Narcotrend (NT) monitoring
Number of subjects: 245

Group type: COMPARATOR
Intervention: Blinded Narcotrend (NT) monitoring
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 245
Study: 30260990

Group type: EXPERIMENTAL
Intervention: gemfibrozil (1200 mg/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27